PharmTech Talk

Nov 26, 2015
Cambridge Consultants engaged in a workshop-style dialogue with a cross section of senior personnel from both Indian and multinational pharma companies to debate whether emerging markets are an opportunity to drive sustainable growth. Conclusions from the workshop are presented in this article.
Nov 23, 2015
By Pharmaceutical Technology Editors
FDA emphasizes the surveillance aspects of quality metrics to concerned drug manufacturers.
Nov 18, 2015
Robert Califf addresses questions about drug pricing at the Senate hearing to weigh his appointment to be the next commissioner of FDA.
Nov 18, 2015
Experts at the ISPE annual meeting describe best practices, including containment and production in classified spaces.
Nov 06, 2015
Even though rising production and use of generic pharmaceuticals is saving billions for the nation’s healthcare system, policy makers continue to slap the industry with policies it claims will limit product development and sales.
Nov 05, 2015
Biotech boom, niche markets, smaller batch sizes and high potency manufacturing are among the key trends shaping the pharmaceutical industry of the 21st century, according to Christian Treitel from Bosch Packaging Technology.
Oct 30, 2015
Everyone talks about “open innovation,” but without the right working culture it won’t succeed. MeetingZone’s Anthony Prior explains how unified communications can help kick-start the necessary change.
Oct 27, 2015
Despite considerable investment by biotech manufacturers in developing competitive biologics for the US market, gaining FDA approval of these products has turned out to be a slow and complex process.
Oct 13, 2015
By Pharmaceutical Technology Editors
A CPhI report predicts how two potential mega free-trade deals, one among Pacific-Rim countries and the other between the US and EU, could affect pharmaceutical companies.
Oct 13, 2015
By Pharmaceutical Technology Editors
A CPhI report suggests that the pharma industry should be careful not to outsource to lower labor-cost countries rather than investing in manufacturing technology and innovation.
lorem ipsum